story of the week
Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Atezolizumab Plus Bevacizumab Versus Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (Immotion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial
Lancet 2019 May 09;[EPub Ahead of Print], BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, S Bracarda, WM Stadler, F Donskov, JL Lee, R Hawkins, A Ravaud, B Alekseev, M Staehler, M Uemura, U De Giorgi, B Mellado, C Porta, B Melichar, H Gurney, J Bedke, TK Choueiri, F Parnis, T Khaznadar, A Thobhani, S Li, E Piault-Louis, G Frantz, M Huseni, C Schiff, MC Green, RJ MotzerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.